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Prescription opioid misuse is a major public health concern, yet few models exist to 
support engaging community pharmacy patients who misuse opioids. This report describes 
qualitative results from a meeting of experts aimed at developing a behavioral health framework 
for opioid medication misuse in the community pharmacy setting. Themes included screening, 
intervention, prevention, and referral to treatment that capitalize on pharmacists’ knowledge of 
medication management. Interventions should be patient-centered, multidimensional, and 


































Background: Prescription opioid misuse is a major public health concern in the US. Few 
resources exist to support community pharmacists engaging patients who misuse or are at risk for 
misuse.  
Objectives: This report describes the results of the execution of the ADAPT-ITT model (a 
model for modifying evidence-based behavioral interventions to new populations and service 
settings) to guide the development of a behavioral health framework for opioid medication 
misuse in the community pharmacy setting. 
Methods: Pharmacy, addiction, intervention, and treatment experts were convened to attend a 
one-day meeting to review the empirical knowledgebase and discuss adapting the screening, 
brief intervention, and referral to treatment (SBIRT) protocol for addressing opioid medication 
misuse in community pharmacy. Qualitative data gathered from the meeting were analyzed by 2 
independent coders in a 2-cycle process using objective coding schemes. Percentage of 
agreement and Cohen’s Kappa were calculated to assess coder agreement.    
Results: First-cycle coding identified 4 distinct themes, with coder percentage of agreement 
ranging from 93.5-99.6% and with Kappa values between 0.81-0.93. Second-cycle coding 
identified 10 sub-themes, with coder percentage of agreement ranging from 83-99.8% and with 
Kappa values between 0.58-0.93. Identified themes and sub-themes encompassed patient 
identification, intervention, prevention, and referral to treatment. 
Conclusions: Focus of screening efforts in the emerging model should capitalize on 
pharmacists’ knowledge of medication management.  Screening likewise should be 
multidimensional in order to facilitate patient-centered interventions that activate additional 
disciplines able to interface with patients at risk or involved in medication misuse.   
4 
 
Keywords: Opioid misuse, adherence, medication management, qualitative research 
Role of Funding Source: This project was supported by a grant from the Staunton Farm 
























The misuse of prescription opioids has reached epidemic proportions in the US and is a 
major concern for public health. 1, 2 Opioid medication misuse involves diverse behaviors, 
including taking more medication than prescribed, doctor shopping, early refills, use for 
psychoactive effects, and/or use to relieve distress besides pain.3 These behaviors have been 
documented in clinical settings3 and health insurance claims.4 Regular opioid medication 
consumers who have mental, behavioral, and pain conditions have a heighted-risk for engaging 
in opioid medication misuse behaviors.4  
The community pharmacy, a primary location for distribution of opioid medications, 5, 6 
is one potentially effective location to address misuse. The feasibility of this resource is 
supported by their ubiquitous presence throughout communities, and pharmacists are one of the 
most prevalent advanced-degreed health professionals in the nation.7 Notably, pharmacists are 
consistently ranked among the most trusted professionals. 8 Furthermore, patients are receptive to 
receiving behavioral health information from pharmacists, 9 who in turn have positive attitudes 
and motivation to deliver care to those who misuse opioid medications.10   
The busy community pharmacy workflow may be especially adaptable to addressing 
opioid medication misuse by employing the well-established Screening, Brief Intervention, and 
Referral to Treatment (SBIRT) protocol. 11-17 SBIRT integrates screening patients for substance 
use, with 1 or 2 30 -minute sessions to explore the patient’s motivation for change followed, if 
necessary, by referral to more intensive care.  Studies in medical settings have shown that brief 
interventions can reduce prescription medication misuse, including opioid medication 
misuse.18,19   Considering that screening and brief counseling about medications are routine 
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activities within community pharmacy, the SBIRT protocol could be a valuable yet untapped 
possibility for addressing misuse of opioid medications.20  
This potential opportunity is, however, beset by specific challenges, including 
identification/operationalization of opioid misuse behaviors,21,22 co-occurring serious health risks 
such as overdose risk,23, 24 physical dependence,25 and legitimate pain management needs.4, 26-29 
Thus, SBIRT models developed for other substances, such as alcohol and tobacco, cannot be 
simply applied in the community pharmacy setting for addressing opioid medication misuse.  
Skepticism is reinforced by emerging literature showing that brief motivational interventions for 
drug use in primary care settings has inconsistent impact on outcomes.17, 30-32 Accordingly, it is 
timely to modify SBIRT so as to be congruent with the spectrum and severity of problems 
associated with opioid medication misuse and its management in the community pharmacy 
setting. 
Toward this goal, this report describes the results of a meeting of an interdisciplinary 
panel of experts employing ADAPT-ITT (Assessment, Decision, Administration, Production, 
Topical Experts, Integration, Training, and Testing33) to guide modifications of SBIRT for 
opioid medication misuse in the community pharmacy setting. ADAPT-ITT was designed to 
serve as a framework for adapting evidence-based HIV interventions. Similar to other initiatives 
used to modify brief intervention models,34-37 ADAPT-ITT is a framework for modifying 
evidence-based behavioral interventions to new populations or service delivery settings.33  We 
describe herein results of the utilization of the “ADAPT” portion of the model to modify SBIRT 
for the community pharmacy setting to address opioid medication misuse. In addition, the results 
are synthesized into a conceptual framework (Figure 1) that is applicable for integrating patient 
identification, intervention, prevention, and referral to care for patients in the community 
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pharmacy setting who are at risk for opioid medication misuse or who are already engaging in 
this hazardous behavior. 
Material and Methods  
The Consolidated Criteria for Reporting Qualitative Research (COREQ) 38 was followed 
to ensure quality and transparency of the methods and results described in this report. COREQ is 
a checklist consisting of 32 items organized into 3 domains: 1) research team and reflexivity, 2) 
study design, and 3) analysis and findings. With the exception of items not applicable to our 
project (interview guides, repeated interviews, and data saturation), the following methods, 
results, and discussion sections satisfy the COREQ requirements.  
Attendees  
 Eleven experts and 3 practicing pharmacists from the US and UK were invited to 
participate in a one-day intensive video-recorded meeting held at the University of Pittsburgh to 
discuss modification of SBIRT for use in community pharmacy to address opioid medication 
misuse. Attendees were purposively selected and invited based on several criteria, they were: 1) 
known to the lead author (GC) through collaborative academic/research associations (n=10), 2) 
identified through a search of the published literature (n=1), and 3) referred from other experts in 
the field (n=2). Attendants represented expertise in pharmacy, brief intervention, opioid 
addiction, behavioral interventions, and substance abuse treatment (Table 1). GC was also a 
participant in the meeting having expertise in brief intervention and addiction. The diverse 
professional and research backgrounds of the panel members thus enabled obtaining diverse 
perceptions that could be integrated into a SBIRT model appropriate to the community pharmacy 




Procedures employed in the ADAPT Framework 
 Prior to convening the experts and again at its beginning, meeting goals were articulated 
to promote focused discussion and ensure acquisition of accurate comprehensive data.  Table 2 
lists the 8 ADAPT-ITT components, their procedures, and when each was implemented (or will 
be implemented in the case of 6, 7, 8, i.e., the “ITT” portion). The first component, assessment, 
consisted of presentations by a subset of attendees focusing on their areas of expertise as it 
pertains to the goal of the project. Presentation content included brief intervention for drug use in 
primary care, brief intervention for alcohol use in the community pharmacy setting, brief 
intervention for medication adherence in the community pharmacy setting, brief intervention for 
opioid medication misuse in the community pharmacy setting, agonist medication treatment, and 
naloxone-based opioid overdose prevention. The goal of the presentations was to align the 
attendees with respect to the empirical knowledgebase relating to prevention, intervention, and 
treatment of opioid medication misuse in the context of limitations/strengths of modifying the 
SBIRT model.  
The decision component, coordinated through a moderator/discussant, involved 
synthesizing the information contained in the presentations followed by a free-flowing 
roundtable discussion focusing on identifying novel intervention components as candidates for 
inclusion in the adapted SBIRT model. The administration component, conducted by the 
presenters, and guided by GC in the question/answer component of the presentations, examined 
the modifications proposed to adapt SBIRT to the community pharmacy setting.  The production 
component, occurring toward the end of and after the meeting, involved GC collecting 
handwritten notes taken by the attendees, gathering input from other attendees who did not take 
notes but sent comments via email, and establishing a timeline and agenda to review the video 
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transcript and notes. Next, in the topic experts component of the model, drafts of the results and 
summary were sent to the attendees for clarification, revision, and comment. The last 3 
components; integration, training, and testing; are currently in preparation for a pilot study of the 
adapted SBIRT model for the community pharmacy setting.  
[TABLE 2] 
Data Collection and Analysis 
 The data consisted of a video recording of the meeting (6 hours), notes from the meeting 
attendees, and additional notes sent by email. Meeting attendees offered a number of suggestions 
and comments that were related to opioid misuse, addiction, and pharmacy.  The video transcript 
and meeting notes were analyzed in 2 cycles using a coding process led by GC in which specific 
content was identified and tallied. 39 This coding and tallying process was facilitated by creating 
objective coding schemes 40, 41 reflecting the thematic discussion (Table 3). The first cycle 
coding scheme was developed by GC based on his meeting participation and review of the data. 
This scheme encompassed 4 themes: patient identification, intervention, prevention, and referral 
to care. The second cycle coding scheme was developed by GC and a doctoral student research 
assistant (TY) after completing first cycle coding through reviewing and discussing themes and 
patterns that emerged from the first cycle. First cycle coding was carried out by GC and TY. 
Second cycle coding was carried out by TY and a masters -level student research assistant (JR). 
TY and JR were trained on coding schemes by GC in one-on-one meetings before and during the 
analysis process in which concepts were reviewed and discussed. Analysis of agreement between 
coders was conducted using percentage of agreement and Cohen’s Kappa (K).  K agreement 
levels of 0.0-0.2 were considered slight, whereas those between  0.21-0.40, 0.41-0.60, 0.61-0.80, 
>0.80 were respectively considered fair, moderate, substantial, and near/perfect.42 In addition to 
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these statistics, selected statements from within the dataset are presented to illustrate the various 
ideas and themes that emerged. Data were managed, coded, and analyzed using Nvivo 10.43  
Results 
First Cycle Codes 
Table 3 displays inter-rater agreement from the first cycle and second cycle coding. As 
can be seen, patient identification, intervention, prevention, and referral to care, had a high level 
of agreement ranging from 93.5-99.6% with K values ranging from 0.81-0.93. The most frequent 
topic identified in the first cycle of coding was intervention (n=296), followed by patient 
identification (n=206), referral to care (n=67), and prevention (n=19). Results of the first cycle 
coding were thus deemed informative to be utilized for development of the second cycle coding 
scheme.  
[TABLE 3] 
Second Cycle Codes 
Patient identification. Second cycle coding identified 4 themes that were encompassed 
in the patient identification code (see Table 3). The first theme focused on defining and 
operationalizing the target behavior(s) for screening. Although the panelists recognized the 
importance of screening for a variety of medications and use patterns, the consensus 
recommendation was to focus screening within the pharmacist area of expertise, namely 
prescribed opioids with particular emphasis for risk of adverse drug events.  With respect to 
opioid medications, the most important adverse events are misuse, addiction, and overdose.  
Inquiring about consumption behavior and adherence to the prescribing regimen can, 
however, be challenging in the pharmacy setting.  In particular, the attendees noted that 
community pharmacists have a dual role of screening/monitoring and “policing” aberrant 
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behavior—that is to say—tracking and reporting illegal or suspicious behavior.  This dual 
responsibility is stressful and formally extends the boundaries of professional practice.  One 
participant commented: “I don’t think the pharmacist… should be in a legal role. Or, they can’t 
be in both [a helping and a legal role]. It’s going to be hard to be in both, manage both.”   
The discussion within the meeting that could resolve this tension was the central point 
within the third identified theme.  Specifically, electronic surveys in kiosks and/or health record 
screening to meet busy community pharmacy workflow demands were discussed as tools to 
lessen the “policing” role of the community pharmacist. Rather than directly interview the 
patient about opioid use patterns in context of adherence to the prescription regimen, the 
pharmacist would instead discuss with the patient the results of a health screening. As one 
participant noted: “…the pharmacist basically gets data from a person at a kiosk, sits down, and 
begins with the statement that, ‘this is what you are telling me about yourself. Where do we 
begin?’ The consultative role of the pharmacist is with the data.” 
In the context of problem identification, the fourth theme thus addressed the need for 
comprehensive screening. The rationale for a broader health perspective rather than 
circumscribed focus on drug use behaviors was based on understanding that patients at risk or 
misusing opioid medications commonly evince a spectrum of problems. Comprehensive 
screening is therefore a requisite for pharmacists to document the factors predisposing to risk for 
or sustaining hazardous use of opioid medications.   
Intervention. Given the complexity of patient behaviors, meeting attendees discussed at 
length the variety of behaviors that might be targeted for intervention. Although clear consensus 
was not reached, second cycle coding of the intervention portion of the discussion identified two 
themes, which from the pharmacist perspective are essential to intervention. First, interventions 
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must capitalize on the pharmacist’s strengths, such as medication review. This task builds on the 
core competencies of the pharmacists’ specific knowledge about medications and their 
interactions.  Moreover, medication review aligns with community pharmacy workflow.  One 
participant asserted: “…pharmacists [could]… support patient safety with respect to prescription 
opiate use based upon dose/type/other medications being used/disease status. This could be built 
from a Comprehensive Medication Review.” 
The second theme explored the concept of patient-centered interventions. This discussion 
examined the importance of asking patients their preferences regarding the focus of any 
proposed intervention. One participant urged: “The sessions must be negotiated from a menu of 
alternatives, which are taken directly from the patient’s perception of the problem, or if possible, 
reframed by the interventionist in a way that is agreeable to patients.” 
Prevention. The third theme in second cycle coding, prevention, identified 2 themes: 
first, preventing patients from proceeding to addiction, and second, averting overdose. 
Prevention of overdose was discussed primarily in relation to training pharmacists in naloxone 
rescue. One participant commented: “…we talk about prevention of overdose, of saying hey, if 
you are going to have [opioid] medications available to you; they’re going to be in your home; 
we need to get some ancillary type of medications in your home to reverse an overdose.” 
Referral to treatment. The referral to treatment discussion also focused on 2 themes. 
The first was reconnecting patients to prescribers for higher levels of care (e.g., agonist 
treatment). The second was connecting patients with physical, behavioral, and/or mental health 
conditions to health professionals. One participant remarked: “If it’s going to get complicated 
really fast, you’re going to want to do something there [that] connects the person to a [health 
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care] team that includes...the pharmacist, the primary care clinician, the nurse in the primary 
care clinician’s office, the social worker or behavioral specialist....”  
Discussion 
Themes coded in the first and second cycle coding process possessed high levels of inter-
rater agreement and K values—thus demonstrating consistency and salience of the topics 
pertinent to pharmacist-based intervention for opioid medication misuse.  Considered in 
aggregate, the results have several implications for a community pharmacy-based model for 
opioid medication misuse. Specifically, the components of an integrative framework, shown in 
Figure 1, underscore the importance of joining drug-specific and medical/psychological 
screening spanning 4 main levels of severity, ranging from no risk to addiction—thus setting the 
stage for a practical patient-centered work plan for addressing opioid medication misuse in the 
community pharmacy setting.   
One of the most frequently discussed themes, patient identification, emphasized the 
importance of capitalizing on the pharmacist’s expertise, especially promoting adherence to the 
prescription regimen and preventing adverse drug events. Consuming more medication than 
prescribed, detecting early refills, and inappropriate use of medications are within the scope of 
pharmacists’ training and expertise. Opioid medication misuse often co-occurs with multiple 
health problems, which may lie outside pharmacists’ competencies. Accordingly, identification 
of high-risk or medication abusing patients must be comprehensive. Multidimensional 
information ideally would be captured using electronic methods such as kiosks and/or health 
record review. Electronic patient identification methods also have the benefit of removing the 
policing burden form the pharmacist, particularly considering that pharmacists report they 
believe patients would respond to electronic screening more favorably than face-to-face 
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methods.10 Although not a strong theme of this project, attendees did note that comprehensive 
screening should employ measures that take into account burden of time on both the patient and 
the pharmacy.  
 Discussion also explored the role of the pharmacist on intervention.  Medication 
management emphasizing adherence to the prescription regimen and safety are core professional 
activities that could readily be accommodated into intervention practice.20  Results from clinical 
trials demonstrate that pharmacists providing medication management can significantly improve 
the health behaviors of pateints.44, 45 A recent systematic meta-analysis located 44 medication 
therapy management (MTM) studies that suggested consistent improvement in behaviors such as 
medication adherence while lowering health care costs.44 MTM, consensually accepted in the 
pharmacy field as helpful to patients,45 has been codified into standardized guiding principles46, 
47 and is supported by both some commercial insurance products and Medicare.48 Moreover, 
substance abuse screening and intervention can be easily incorporated in interventions that 
pharmacists provide within MTM.45 Brief “targeted” MTM interventions are also becoming 
more common and could likewise be implemented to address opioid medication misuse.49 
Altogether, addressing opioid medication misuse by adapting the SBIRT model in the pharmacy 
setting entails conceptualizing the task as screening, intervening, prevention, and referring (if 
necessary) to manage medications so as to improve adherence and safety.  
A patient-centered approach to intervention emphasizes the unique circumstances of each 
patient.  Whereas the community pharmacy may be a readily accessible starting point for 
intervention, many factors beyond pharmacists’ scope of practice spanning addiction, medical 
problems, social adjustment, and family problems may also be undergirding hazardous use of 
opioid medications.   Consequently, the pharmacist needs to be included within a team-based 
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model of patient care that includes physicians, nurses, physical/occupational therapists, and 
social workers/behavioral health providers. A team-based approach to health care is an emerging 
model that is currently at varying levels of adoption within the larger health care environment.  
The new idea suggested in this project is that the community pharmacy should be included as an 
entry point of patient engagement.  
Limitations 
Several limitations of this study should be noted.  The attendees represented a variety of 
training and practice backgrounds that, although producing rich discussion, may have under-
emphasized the importance of the pharmacist's perspective.  These rich discussions therefore did 
not allow for the group to come to a clear consensus regarding details of a pharmacy-based 
intervention for opioid misuse. However, a clear framework arose as a guide to future delineation 
of a specific intervention protocol. Furthermore, the attendees in the Topical Experts portion of 
the ADAPT-ITT process were not required to review the entirety of the data in their assessment 
of these results.  Rather, the attendees were asked to review only the results presented herein. All 
files were made available to attendees for their review if they wished to examine raw data. 
However, given the high level of agreement between the coders, the schemes and the data are 
considered to be accurate representations of the discussion.   
Conclusion 
 A one-day intensive meeting was convened to review the empirical knowledgebase and 
discuss adapting the SBIRT protocol for opioid medication misuse in the community pharmacy 
setting. Discussions explored patient identification, including comprehensive assessment using 
electronic methods to fit within community pharmacy workflow and to avoid involving the 
pharmacist in a policing role.  Adaptation of SBIRT for community pharmacy concentrated on 
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capitalizing on the pharmacist’s knowledge of medication management, particularly related to 
adverse events and medication adherence.  However, patients who misuse opioid medication 
often have problems that exceed the core competencies of the pharmacist. Interventions for acute 
needs should be team-based and encompass the range of disciplines that interface with 
medication misuse.  Furthermore, a patient-centered intervention model is recommended 
whereby the factors that uniquely contribute to individual onset and maintenance of opioid 
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Table 1. Expertise of attendees (n) 
Opioid overdose prevention and harm reduction expert (1) 
Health services pharmacy expert (1) 
Pharmacologic opioid treatment expert (1) 
Practicing addiction pharmacist (1) 
Psychosocial addiction treatment expert (1) 
Practicing community pharmacists (2) 
Behavioral intervention experts (3)  






















Table 2. ADAPT-ITT framework for modifying SBIRT in the community pharmacy setting 
for opioid medication misuse 
Model 
Component Objective Executed  
1. Assessment Presentations by attendees Scientific working 
session  
2. Decision Discussant summarization and roundtable discussion of needed 
intervention components  
Scientific working 
session  
3 Administration Topic specific discussion on needed changes to screening, 
intervention, prevention, and referral to treatment 
Scientific working 
session  
4. Production Gather written notes Scientific working 
session/post scientific 
working session  
 Plan review of video recordings 
 Plan writing up meeting proceedings and adapted SBIRT model 
  Analyzing and writing up meeting results Post scientific working 
session 
5. Topic Experts Sending results to meeting attendees for review Post scientific working 
session   Revising manuscript based on feedback 
6. Integration Incorporate SBIRT model into research protocol Post scientific working 
session 
7. Training Training approach/methods in research protocol Post scientific working 
session 

















Table 3. Coding schemes and inter-rater agreement  
First cycle codes Second cycle codes 
% 
Agreement Kappa 
Total n of 
codes 
Patient identification   97.3 0.88 206 
 
Operationalize target behavior 93.7 0.63 66 
 
Policing role 99.8 0.84 12 
 
Use EHR or electronic screen 99.5 0.78 9 
 
Comprehensive assessment 96.9 0.63 40 
Intervention   93.5 0.81 296 
 
Building on pharmacy strengths 87.6 0.60 67 
 
Patient-centered intervention 83.0 0.58 52 
Prevention   99.6 0.92 19 
 
Prevention of SUD 99.7 0.91 23 
 
Overdose prevention 97.3 0.84 20 
Referral to care   99.5 0.93 67 
 
Refer to professionals to assist in follow through 99.1 0.63 21 

















Figure 1.  Targeted intervention framework within community pharmacy workflow 
 
 
 
 
 
 
 
